amfAR, The Foundation for AIDS Research

HIV Treatment Clinical Brief: Dolutegravir

Dolutegravir (DTG) is a well-tolerated antiretroviral that is effective at suppressing HIV, can be taken once a day, and has a high barrier to resistance. It is increasingly recognized as a potential first-line treatment option for HIV. DTG belongs to the class of antiretroviral medicines called integrase inhibitors (INIs) or integrase strand transfer inhibitors (INSTIs). Integrase inhibitors work by blocking integrase, the enzyme required for HIV to insert its viral DNA into the DNA of a host CD4 cell.

This clinical brief provides guidance on the use of DTG in varying adult and pediatric populations.

Download the full PDF by clicking here or the image below.

HIV Treatment Clinical Brief - Dolutegravir 500